What is OSTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.08B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for OSTX?

P/E (TTM) is n/a and 52-week range is $1.15 to $2.25 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s OSTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for OSTX?

The company profile lists net income (TTM) near $-49M, EPS (TTM) near $-1.07 when available from the market-data feed. Figures are informational and may lag live markets.

Where is OS Therapies Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Rockville, Maryland, US, 45.5M shares outstanding, ISIN US68764Y2072 when available from company profile and filing metadata.

OS Therapies Inc

$OSTX

Health Care · Biotechnology

Run Scenarios

$1.62

+0.00%

OS Therapies Inc

$OSTX

Health Care · Biotechnology

Run Scenarios

$1.62

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.

Employees

5

Website

ostherapies.com/

IPO

2024-08-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NYSE MKT LLC

ISIN

US68764Y2072

Headquarters

Rockville, Maryland, US

Shares outstanding

45.5M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

6.25%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.

Employees

5

Website

ostherapies.com/

IPO

2024-08-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)